In the brains of AD patients, the expression levels of GPLD1 were not changed, compared with those in healthy human brains, but interestingly, GPLD1 in the cerebrospinal fluid of AD patients shows a lower molecular weight compared with that of healthy individuals (29), suggesting abnormalities in post-translational modifications such as glycosylation. This evidence concerns the gene GPLD1 and Alzheimer disease.